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Background: Anal cancer is a priority health issue in HIV positive men who have sex with men. Anal cancer
screening may be aimed at either detecting the precursor lesion (high grade anal intraepithelial neoplasia(HGAIN))
or early anal cancer. To date no qualitative study has explored the views of HIV physicians regarding anal cancer
and its screening.
Methods: We conducted indepth interviews with 20 HIV physicians (Infectious diseases, Immunology, Sexual
health, General practice) in different settings (hospital, sexual health centres, general practice) from around Australia.
Framework analysis was used to identify themes.
Results: HIV physicians viewed anal cancer as a significant health issue and all agreed on the importance of anal
cancer screening amongst HIV positive MSM if a valid screening method was available. Barriers for utilizing anal
cytology was based primarily on the theme of insufficient evidence (e.g. no studies demonstrating reduction in
mortality following screening or effective treatments for HGAIN). Barriers for utilizing DARE for early cancer detection
were based on systemic factors (e.g. lack of opportunity, lack of priority, differences in HIV care practices); health
provider factors (lack of evidence, difficulty discussing with patients, lack of confidence in DARE) and patient factors
(perceived discomfort of DARE for patients, low anal cancer risk awareness). Physicians were willing to consider the idea
of patient self-examination and partner-examination although concerns were raised regarding its reliability and issues
surrounding partner dynamics.
Conclusions: HIV physicians remain ambivalent regarding the most effective means to screen for anal cancer. More
research is needed to address the physicians’ concerns before anal cancer screening can be implemented into routine
HIV care.
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Anal cancer occurs at higher rates in men who have sex
with men(MSM) than in the general population [1] and
with higher rates again in HIV-positive MSM [2]. Rates
of anal cancer in HIV-positive MSM have been reported
as high as 112 to 144 per 100,000 person years [3,4].* Correspondence: j.ong@unimelb.edu.au
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unless otherwise stated.This is more common than other cancers such as colorec-
tal cancer (73 per 100,000 person years) and lung cancer
(55 per 100,000 person years) in the general population
[5]. Anal cancer is now the most common non-AIDS-
defining malignancy in those living with HIV [6].
Although anal cancer is seen to be important by HIV
clinicians, few are actually screening for anal cancer [7].
There are several potential methods of screening being
considered. Firstly, given the success with cervical cancer
screening using cytology [8], anal cytology screening tois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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neoplasia(HGAIN) has been proposed [9]. Secondly, some
suggest that those at greatest risk for anal cancer (i.e. HIV-
positive MSM) should be targeted with an annual digital
ano-rectal examination(DARE) to detect early anal cancer
[9-11]. If anal cancer is detected at an early stage, there are
survival advantages with 5-year relative survival rates being
78% for localized anal cancer, 56% for regional disease and
18% for metastatic disease [12,13]. Thirdly, a novel means
of early detection may be to encourage patients to detect
early signs of cancer themselves or with the aid of their
partner [11]. Although there is no research to support the
efficacy of employing such methods, physicians often de-
scribe how patients would present because of an unusual
lesion they have found themselves [14]. A further explor-
ation of self- and partner-examination is warranted as they
may become a useful adjunct to anal cancer screening.
To date, there are no published qualitative studies ex-
ploring the views of HIV physicians regarding anal cancer
and its screening. We sought to gain an in-depth under-
standing of how key HIV clinicians view anal cancer and
its screening using the methodologies described above.
Methods
Participants
Semi-structured in-depth telephone interviews were
conducted with HIV physicians throughout Australia.
Health care services for Australians living with HIV are
provided in hospital based settings (Infectious Disease,
Immunology specialists) or community based clinics
(Sexual health physicians, high-HIV caseload General
Practitioners(GP)) [15]. Purposive sampling (i.e. selective
sampling that identifies particular characteristics of the
study population) was used to maximize diversity of
physicians. Selection was based on characteristics that
the authors discussed and agreed upon that may poten-
tially influence views on anal cancer screening - fulltime
or part-time work, setting of HIV care, specialty and
gender of the physician. We interviewed physicians until
data saturation was reached (i.e. when additional inter-
views did not shed any further light on the issue).
Procedure
Physicians from major HIV clinics in each state were
approached via an email containing study participant in-
formation and consent form. If consenting, the interview
was conducted over the phone(JO) using a pre-piloted
semi-structured questionnaire. Structured questions cap-
tured physicians’ demographic data and the remainder
of the interview contained open questions aimed at eli-
citing physicians’ understanding and attitudes towards
anal cancer and its screening. Screening was defined as
1) using anal cytology and 2) early cancer detection
using an annual DARE, self-examination and partner-examination. This study focused on anal cancer screen-
ing in HIV-positive MSM population.
Analyses
Data were transcribed, organized electronically and
assigned codes using NVIVO (QSR International Pty Ltd,
version 10.0, 2012), a qualitative research software pro-
gram. Data were analyzed using an iterative approach.
After each interview a preliminary analysis was performed
to allow the follow up of emerging issues to be included in
subsequent interviews. Once all interviews were com-
pleted, content analysis was performed to group and label
the data in order to identify emerging themes. Coding was
conducted independently by two researchers(one sexual
health clinician, one sexual health researcher) and then
discussed with the research team to achieve consensus on
common themes. Finally, coding for themes and concepts
was used to frame the remaining data. We adhered to the
qualitative research review guidelines (RATS) [16] in
reporting the findings of this research.
This research was approved by the Alfred Health Human
Ethics Committee (Project 31/13).
Results
Of 22 physicians approached, two did not reply to the
invitation email and one suggested another physician in
their clinic. Demographics are summarized in Table 1. Il-
lustrative quotes include gender, specialty and years in
HIV practice of the participant (YiHP).
Physicians’ understanding of anal cancer
Participants had an excellent grasp of causation, risk groups
and rates of anal cancer. Almost all spoke of increasing age,
human papillomavirus and smoking as important risk fac-
tors. Anal cancer was seen by all as a disease of concern.
…a devastating infection (F, Sexual health, 15 YiHP)
…potentially very nasty (M, General Practice, 28 YiHP)
…the last 25 years the rates have almost doubled I
guess in Australia and similar patterns have been seen
around the world (M, Infectious Disease, 15 YiHP)
Virtually all HIV physicians specifically identified HIV-
positive MSM as the most at-risk group for anal cancer.
However some (especially general practitioners) expressed
discrepancy between reported rates and their own personal
practice:
…I suspect the numbers have increased a bit over the
last five or 10 years but they haven’t gone up like
everyone was predicting where we were going to see
an avalanche (M, General Practice, 28 YiHP).
Table 1 Demographics of HIV physicians
Number of HIV physicians
State









- High HIV case-load
General practitioner
7
- Sexual health physician 7






Mean age = 51.6 years (range 35–61).
Mean duration of working with HIV patients = 21.6 years (range 5–34).
Mean number of HIV patients seen per week = 19.4 men (range 1–50).
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group was that targeting screening for HIV-positive
MSM was important. There was an underlying sense of
urgency that something should be done.
…you’ve got a cancer that’s 100 times more common
[in HIV-positive MSM compared with the general
population] then we should be trying to do something
about it (M, Infectious Disease, 27 YiHP)
Views on anal cytology
The major theme expressed when discussing cytology
screening for HGAIN was the lack of convincing evidence.
…still done on the basis of belief rather than evidence
(M, Immunologist, 30 YiHP)
Issues of concern included the absence of evidence for
screening using cytology in reducing morbidity and mor-
tality from anal cancer; the high prevalence of AIN in
HIV+ MSMs and thus the concern of subjecting large
numbers of patients to unnecessary investigations; and
the lack of availability for patients to have a high reso-
lution anoscopy as follow up to an abnormal anal cy-
tology. Participants noted the uncertainty around the
natural history of AIN, the effectiveness of treatments
and whether treating HGAIN would make a difference
to anal cancer rates.…just about all gay men with HIV will have abnormal
cells and the natural history of those abnormal cells is
still not understood enough really so we don’t know
what to do once we’ve found those abnormal cells
(M, General Practice, 22 YiHP)
Reflected in this reluctance to initiate anal cancer
screening was a very strong theme calling for more evi-
dence or guidelines before such screening should be in-
troduced for HIV patients.
…one of the problems is that the current guidelines
that we have in Australia don’t recommend any form of
anal cancer screening (M, General Practice, 23 YiHP).
…screening tests require a much higher level of
evidence than even treatment studies (M, Sexual
Health, 34 YiHP)
Views on DARE
Given the reluctance of HIV physicians in Australia to
implement anal cancer screening using anal cytology,
further interviewing enquired about the possibility of
implementing an early cancer detection program instead.
This was proposed as an annual visual inspection of
peri-anal region together with a digital ano-rectal exam-
ination(DARE) by the HIV physician. It was interesting
that the initial response from the majority (across all
specialties and years of HIV experience) were positive.
…probably best practice (M, Immunologist, 30 YiHP)
…reasonable thing to do (F, Infectious Disease, 23 YiHP)
…correct means by which we should be screening…
should be embraced (M, General Practice, 30 YiHP)
…sensible, cheap and easy thing to do
(F, Immunologist, 5 YiHP),
…it’s going to pick up lumps that may well be early
cancers and I guess that’s where the efforts should be
made, really (M, General practice, 22 YiHP)
But despite the enthusiasm for DARE, the majority of
HIV physicians admitted to not doing this routinely for
their population of HIV positive MSM.
…I do it very rarely unless someone has symptoms
(M, Infectious Disease, 5 YiHP)
When asked to elaborate why there was this discrepancy
between the idea that DARE is a good one with the actual-
ity of implementing DARE into routine care, multiple
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health provider and patient. Table 2 provides a summary
of major themes under each of these headings.
1) Systemic barriers
A strong theme that emerged was the absence of a
clinical routine to incorporate DARE. Thus ‘the main
barrier is forgetting to do it’ (F, Sexual health, 12 YiHP).
Physicians stated they had lost the opportunity to offer a
DARE during checks for sexually transmitted infections
as the option for self-collected anal swabs had increased
in recent years.
…now we’re getting people to self-collect all of the
specimens at sexual health screens which I think is
terrible because it means that often nobody looks
(M, General practice, 23 YiHP)
This was compounded by the need to manage the
complexities and competing interests of multi-morbidity
seen in an ageing HIV population. Many physicians talked
about the difficulties in delivering what is recommended
already in the guidelines(e.g. screening for cardiovascular
complications) and it seemed that anal cancer was not al-
ways a priority.
…often when you're time poor and there’s other more
pressing issues that the patient wants to discuss…
[DARE] may be something that gets missed
(M, Sexual health, 15 YiHP)
The frustration over lack of time was almost palpable
in some, whilst not an issue for others:
…it’s just one more thing that needs to be done in too
little amount of time (M, GP, 30 YiHP)
…it’s only once a year. Your average consultation now
with a HIV patient is nowhere near as cluttered as it
was 10 years ago… so it [DARE] wouldn’t be that bigTable 2 Major themes of barriers for implementing DARE
Systems factors Lack of opportunity
Unclear referral pathway
Differences in HIV care practices
No financial incentives
Health provider factors Lack of evidence
Difficulty discussing with patients
Lack of confidence in DARE
Patient factors DARE discomfort
Low anal cancer risk awarenessan intrusion. It would add a minute or two to the
consultation (M, Sexual health, 34 YiHP)
Another frustration for some physicians was the lack of
clarity around who should be conducting the screening and
where to send patients presenting with symptoms of con-
cern. It was noted that in Australia, HIV patients may be
cared for by different specialists(Infectious Disease, Immun-
ology, Sexual health physicians or General Practitioners
(GP)) in various settings(hospital or sexual health centre or
GP) and that some patients can be under the care of more
than one specialist. A consequence of this can be the as-
sumption that another doctor is doing the anal cancer
screening.
…where does that responsibility - who does it lie with?
I guess for some people they potentially would fall
through the cracks in the system in that we’d say it was
the GPs and the GP would say it was ours (F, Sexual
health, 25 YiHP)
Some participants perceived that differences inherent
in specialty training and care setting could be a barrier
with the Infectious Diseases and Immunology trained
physicians being less comfortable and their practice set-
ting not readily set up for DARE.
…being a sexual health physician we don’t mind
looking at bums at all… That could be quite different in
a hospital outpatient environment for instance… ID
clinics, as you know, have always avoided going
anywhere near the genitalia (M, Sexual health, 34 YiHP)
One hospital physician suggested that GPs who effectively
run small businesses are incentivized by payment systems
for shorter consultations, which could act as a barrier.
…GPs won’t do it because there’s no money in it… if
you’ve got to spend two or three minutes getting
somebody undressed and doing an exam and then
explaining their result then that’s time that the GPs
won’t want to spend (M, Immunologist, 24 YiHP)2) Health provider barriers
At the health provider level, a prominent theme was the
current lack of published evidence for DARE primarily to
do with its effectiveness in detecting early anal cancer and
the cost-effectiveness of implementing this into routine
HIV care.
…everybody would need to be convinced that the
evidence was strong enough (M, Immunologist,
24 YiHP)
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sicians expressed difficulties in initiating the topic of
anal cancer screening with patients.
…I must admit it’s not easy for me to bring that one
up (F, General practice, 19 YiHP)
…feel awkward in raising the issue (M, Immunologist,
24 YiHP)
In terms of the procedure of DARE itself, it was pre-
dominantly the sexual health physicians who discussed
doubts about their ability to pick up early cancers. But
in general there was consensus by all participants re-
gardless of their specialty, that they would benefit from
more training in utilizing DARE for detection of anal
cancer.
…given that it could be very small and you want to
pick it up early otherwise you lose a lot of the benefit.
So I don’t think it’s a very sensitive method. Also it’s so
user dependent and I can’t see that I would feel
confident in it (F, Sexual health, 15 YiHP)
Most of us learn it [rectal exams] on the wards as an
intern for constipation and prostate checks… I think the
actual checking for anal cancer is more detailed …and I
don’t have a good handle on exactly what to feel for,
what to worry about, what not to worry about, all that
kind of thing (F, Immunologist, 5 YiHP)
3) Patient barriers
At the patient level, two main themes emerged. Firstly,
physicians reported that there may be a level of patient
discomfort in receiving a DARE. This may be due to per-
ceived patient embarrassment, patients not feeling pre-
pared for the examination and potential issues with past
history of sexual assault or fear of disclosing sexual
orientation.
…people don’t like to think and talk about it [anal
cancer]… you have to wait until patients become
symptomatic and not embarrassed to talk about
it or show you before it can get diagnosed
(F, Immunologist, 5 YiHP)
…A lot of patients feel it’s a bit of an invasion
(M, General practice, 30 YiHP)
…there have been a few patients where they’ve said
‘oh look I haven’t prepared for that sort of
examination’… the patient had some fears about not
being clean (M, General practice, 29 YiHP)Furthermore several physicians discussed that having a
female physician perform the DARE may be hampered
by patients’ view of regarding them as a maternal figure.
…there’s kind of a relationship builds up which is - it
kind of almost an intimate friendship to some extent…
almost it’s like being an aunt or an older sister… and
you don’t let aunts and older sisters examine your
backside comfortably (F, Infectious disease, 23 YiHP)
The second main theme revolved around the percep-
tion that health literacy concerning anal cancer risk
remained poor in HIV positive MSM populations.
…I think the vast majority wouldn’t know that [anal
cancer is] something that they’re particularly at risk of
(M, General practice, 22 YiHP)
Attitude towards early cancer detection using self- and
partner-examination
We also explored other potential methods for early can-
cer detection. A majority of HIV physicians believed that
self-examination was already occurring amongst HIV-
positive MSM.
…often patients do present because they’ve felt a
lump (M, General Practice, 29 YiHP)
…quite a lot of patients I’ve looked after are quite
adept at examining their perianal region (F, Infectious
Disease, 23 YiHP)
Some discussed the positive aspects of self-examination
as patients becoming more educated, aware and involved
in their own health.
…it definitely gives the patient some responsibility for
their own health which I think is definitely worth it
(F, Sexual Health, 15 YiHP)
…it’s probably a bit like breast cancer screening… that
if they find a lump that’s a good thing if they tell us
about that before we find it in them (M, Infectious
Disease, 5 YiHP)
However, it was not seen as a screening method that
could be solely relied upon as there were issues regarding
potential difficulties of the technique of performing a self-
examination and the ad hoc nature it was being done.
…I don’t think the majority would to do it regularly and
actually report back findings… There’s been campaigns
to get men to do testicular self-examination. By and large
not even that happens (M, Immunologist, 30 YiHP)
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(M, Sexual Health, 22 YiHP)
…they don’t know what they’re feeling and they
haven’t had the chance to be trained
(M, Immunologist, 24 YiHP)
There was also a common perception that partner-
examination was already happening.
…plenty of boys do, as part of foreplay, stick their
fingers in each other’s butts and are probably fairly
familiar with what they feel (M, General Practice,
30 YiHP)
Although it was seen as easier to do in comparison to
self-examination, it was perceived that less patients
would be willing to ask their partner to examine their
anus for a medical reason. Concern was expressed over
the changing role of the partner:
…putting the responsibility on to the partner for the
screening. I don’t think that’s appropriate’ (F, Sexual
Health, 14 YiHP).
It was noted that there may be a blurring of the line
between sexual pleasure and examination for abnormal-
ities, partnerships may not last and partners who are not
trained don’t understand what to feel for. Physicians
stated that the partner finding unusual lesions may in-
crease anxiety unnecessarily for both the patient and
their partner. There was also a risk that if the physician
was out of the loop for screening that significant lesions
may be missed.
…it’s not very romantic to have your partner do it too
often I think. Well you’d need a very good friend at
least’ (M, Sexual Health, 22 YiHP)
Discussion
This study is the first to report qualitative data from
HIV physicians on current views about anal cancer and at-
titudes regarding anal cancer screening in HIV-positive
MSM. It is clear that there is excellent awareness of the
issue of anal cancer amongst HIV physicians from all spe-
cialties with varying years of experience. Consistent with
quantitative studies, there was an urgency that action is
needed [9-11].
Regarding anal cytology, there were two major barriers
highlighted by participants. Logistically, there is a mis-
match between potentially high number of men with an
abnormal result from screening and the paucity of physi-
cians able to perform high resolution anoscopy to follow
up these abnormalities. Currently in Australia, only ahandful of physicians are trained in providing high reso-
lution anoscopy and virtually all are conducted within a
research setting. Secondly, there was a call for greater level
of evidence to demonstrate that treatment of HGAIN re-
duces the incidence of anal cancer and the effectiveness of
treatments of HGAIN to resolve these lesions. Until more
high resolution anoscopists are trained, and anal cytology
is reflected in HIV guidelines supported by a higher level
of evidence than ‘expert opinion’, it seems unlikely that
Australian physicians would utilize anal cytology as a
means of screening.
Whilst the majority of literature is focused on anal
cancer screening using cytology, this study provided de-
tailed views of HIV physicians in implementing an early
cancer detection model using an annual DARE. DARE is
regarded as the principal cancer screening test compared
with anal cytology, which is the principal precursor
(HGAIN) screening test [9]. Some researchers consider
that DARE should be performed in everyone who is at
high risk of anal cancer [11]. However, these recommen-
dations have not been widely reflected in regional or na-
tional HIV guidelines [17]. Although many physicians
were supportive of early detection of anal cancer, they
identified multiple potential barriers at the systems, pro-
vider and patient levels. This highlights that even though
an annual DARE appears to be a relatively simple pro-
cedure, it may not necessarily be easy to implement.
At the systems level, participants discussed the need to
set in place a clear system that is clinic-specific that
makes DARE a routine part of HIV care. There may be
value in utilizing the knowledge gained from system
change literature [18] to mitigate barriers to implemen-
tation. For instance by having a clear system in place, a
Canadian HIV clinic increased its anal cancer screening
either by DARE and/or cytology from 10% to 44% of pa-
tients over 3 years [19]. Furthermore, the provision of
incentives should be explored in different settings if
DARE becomes widely recommended as a routine part
of HIV care as providing incentives has been found to be
important for increasing uptake of other screening tests
such as pap tests and mammograms [20].
Our study suggests that provider level factors must be
addressed. A key barrier was even though DARE is rec-
ommended as a means of early detection of anal cancer
in some guidelines [21,22], the level of evidence pro-
vided is only by ‘expert opinion’. Almost all physicians
remained skeptical over incorporating DARE into rou-
tine care until stronger evidence was made available. To
date, there has been no published data on the sensitivity
and specificity for DARE to detect early anal cancer.
However, anal cancers were detected with an average
size of 2.9 cm at diagnosis in HIV-positive patients, and
most were visible and/or palpable for some time before
definitive diagnosis [23]. Although it is likely that regular
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studies have been published to evaluate whether it is
cost-effective and would lead to a reduction in morbidity
and mortality from anal cancer. As physicians in this
study highlighted, these data must be shown before
DARE becomes widely adopted. Although participants
were comfortable with performing a rectal examination
for prostate cancer screening, using DARE for anal can-
cer screening was seen as a new skill that required extra
training. Instead of bypassing the anal canal to examine
the prostate, physicians now have to learn to feel the en-
tirety of the anal canal and identify the presence of any
lumps or ulcers that may potentially be anal cancer.
Physicians had a perception that patients may find
DARE uncomfortable. This was not surprising and was
consistent with other screening programs involving genital
examination – cervical pap smears [24] and mammogram
[25]. Physicians involved in an anal cancer study also
expressed concern that some patients may worry about
being clean for the examination [26]. Therefore, one strat-
egy to increase the uptake of DARE may be to allow time
for patients to prepare psychologically and physically for
the examination. This may involve telling patients that a
DARE is due at their next visit or give them the option to
clean themselves before doing the DARE.
Self-examination and partner-examination are poten-
tially novel ways of screening for anal cancer. Whilst
there are data for self-examination for breast cancer
[27], skin cancer [28], and testicular cancer [29], this is
the first published study exploring the views of HIV phy-
sicians regarding self- and partner-examination as modes
for early anal cancer detection. Physicians were open to
discuss the concept of these novel screening methods
and if the issues raised in this paper can be addressed,
they may prove to be a useful adjunct to anal cytology
and/or DARE. For example, in addition to regular screen-
ing by a physician, patients may be educated in how to
self-examine and/or recognize potential symptoms of anal
cancer and be encouraged to present to the physician be-
tween their regular scheduled physician screening. How-
ever, as with DARE, more research is needed to test its
efficacy and acceptability before this is recommended to
patients.
Despite multiple barriers identified in this study, these
are not insurmountable and can be addressed. For in-
stance, at the systems level, having a clear reminder sys-
tem, a clinic champion (to encourage screening) and clear
referral pathways may help to facilitate more men being
screened. At the health provider level, the provision of
more research evidence and training may help physicians
feel more confident in conducting screening. And at the
patient level, strategies to improve their awareness of anal
cancer risk and allowing adequate preparation time before
screening may facilitate greater uptake of screening.In common with all qualitative studies, the findings
are context dependent. However the inclusion of HIV
physicians with different backgrounds and work settings
across Australia has offered a broad range of viewpoints.
This study has provided detailed information about
current issues that need to be addressed before anal can-
cer screening be implemented. It may be useful to ex-
plore how widely these views are held in a quantitative
study of a larger number of HIV physicians. The other
limitation pertains to the current Australian practice of
not offering anal cancer screening outside a research set-
ting. This meant that the vast majority of physicians
interviewed were not participating in any anal cancer
screening and thus influenced the tone of the study with
multiple barriers identified. Future research to specific-
ally include physicians from overseas who are actively
screening may provide insights into facilitators of anal
cancer screening.
Conclusion
The best method for anal cancer screening is still an
area of uncertainty for HIV physicians in Australia.
More evidence (e.g. of reduction in mortality and mor-
bidity of anal cancer as a result of screening) may be
needed for anal cytology and DARE before it is imple-
mented. Inclusion of an annual DARE as targeted
screening for HIV-positive MSM may not be easy to im-
plement with multiple barriers needing to be addressed.
Consideration may be given to self-examination and
partner-examination as adjuncts to screening if issues of
its reliability could be addressed and if partners would
feel comfortable and competent to take on this role.
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